ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIRO..CY..TRBGCZEEHUPLSK....IS..............................*JBDM Ver 0.1.59 (03 Mar 2017) - 2999001/01934608CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120170719W173deBibliographieenBibliographyfrBibliographieEP06824918.4200609082008033120150119enenen714865 P20050908US2017071920172920080625200826201703152017112016081720170719201729G06F 7/00 20060101AFI20140407BHEP G01N 33/50 20060101ALI20140407BHEP G01N 33/564 20060101ALI20140407BHEP G01N 33/68 20060101ALI20140407BHEP G01N 33/574 20060101ALI20140407BHEP deGEZIELTE IDENTIFIKATION IMMUNOGENER PEPTIDEenTARGETED IDENTIFICATION OF IMMUNOGENIC PEPTIDESfrIDENTIFICATION CIBLÉE DE PEPTIDES IMMUNOGÈNESWO-A1-94/20127US-A- 5 726 023US-A1- 2004 018 971US-B2- 7 179 645KNUTSON K L ET AL: "Tumor antigen-specific T helper cells in cancer immunity and immunotherapy", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 54, no. 8, 1 August 2005 (2005-08-01) , pages 721-728, XP019333158, ISSN: 1432-0851, DOI: 10.1007/S00262-004-0653-2ABRAHAM MITTELMAN ET AL: "Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome", INTERNATIONAL JOURNAL OF CANCER, vol. 98, no. 5, 10 April 2002 (2002-04-10) , pages 741-747, XP055111438, ISSN: 0020-7136, DOI: 10.1002/ijc.10259DAKAPPAGARI N K ET AL: "Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 60, no. 14, 15 July 2000 (2000-07-15) , pages 3782-3789, XP002290184, ISSN: 0008-5472RAMASAMY R ET AL: "Characterisation of an inhibitory monoclonal antibody-defined epitope on a malaria vaccine candidate antigen", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 23, no. 4, 1 February 1990 (1990-02-01), pages 305-309, XP023668953, ISSN: 0165-2478, DOI: 10.1016/0165-2478(90)90077-4 [retrieved on 1990-02-01]WAGNER C ET AL: "Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2", CANCER IMMUNITY, ACADEMY OF CANCER IMMUNOLOGY, CH, vol. 3, no. 18, 1 December 2003 (2003-12-01), pages 1-15, XP002486698, ISSN: 1424-9634N. K. Dakappagari: "Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities", Journal of Biological Chemistry, vol. 280, no. 1, 1 January 2004 (2004-01-01), pages 54-63, XP055047782, US ISSN: 0021-9258, DOI: 10.1074/jbc.M411020200ZUM BUSCHENFELDE C M ET AL: "Antihuman Epidermal Growth Factor Receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 62, no. 8, 15 April 2002 (2002-04-15) , pages 2244-2247, XP002981803, ISSN: 0008-5472KONO K ET AL: "Trastuzumab (Herceptin) Enhances Class I-restricted antigen presentation Recognized by HER-2/neu-specific T Cytotoxic Lymphocytes", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 10, no. 7, 1 April 2004 (2004-04-01), pages 2538-2544, XP002981804, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-03-04242014041117159896.420170308PONNIAH, Sathibalan7008 Golden Seeds RowColumbia, MD 21044USPEOPLES, George, E.9465 Lovat RoadFulton, MD 20759USSTORRER, Catherine, E.6437 Lochridge RoadColumbia, MD 21044USFLORA, Michael5172 Almeria CourtMt. Airy, MD 21771USThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.101306527HE47A02/P-EP6720-A Rockledge Drive, Suite 100Bethesda, MD 20817USSteinecke, Peteret al101276620Müller Fottner Steinecke Rechtsanwalts- und Patentanwaltspartnerschaft mbB Römerstrasse 16 b52428 JülichDEATBEBGCHCYCZDEDKEEESFIFRGBGRHUIEISITLILTLULVMCNLPLPTROSESISKTRUS200603517120060908enWO200703077120070315200711